TPO and idiopathic aplastic anemia: Short-term efficacy and safety of afatrombopag conversion therapy in patients with aplastic anemia(AA)who were previously ineffectively treated with intense immunosuppressive therapy(IST)combined with TPO receptor Agonist(TPO-RA)or who were unable to tolerate the side effects of TPO-RA.